Objective-To evaluate the requirement for protein kinase C (PKC ) in the development of lupus in mice, and to explore the potential of targeting PKC as a therapeutic strategy in lupus.
Conclusion-This study identifies PKC as a central mediator of lupus pathogenesis, suggesting that PKC represents a promising therapeutic target for the treatment of systemic lupus erythematosus. Moreover, the results indicate the feasibility of using a PKC inhibitor for the treatment of lupus.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the production of autoantibodies and damage to multiple organs. B cells represent important therapeutic targets in SLE, because they have several pathogenic functions, including autoantibody production and antigen presentation to T cells, resulting in differentiation of Th17 cells and proinflammatory cytokine production (1-3).
Both B cell receptor (BCR)-and BAFF-dependent signals are required for B cell differentiation and mature B cell maintenance (4) (5) (6) . These signaling pathways are also critical for the enforcement of B cell tolerance (7) (8) (9) . One of the major survival pathways mediated by BCR and BAFF is activation of the transcription factor NF-B, which mediates up-regulation of antiapoptotic proteins such as Bcl-2, Bcl-x L , and A1, as well as downregulation of proapoptotic proteins. However, exaggerated NF-B activation and prolonged B cell survival can lead to the generation of deleterious autoimmune responses, as shown in transgenic mouse models of Bcl-2 and Bcl-x L over-expression (10) .
Protein kinase C (PKC ) is a serine/threonine kinase expressed in normal and malignant B cells (11, 12) . It plays an important role in mature B cell survival through the BCR-mediated NF-B activation pathway (13) (14) (15) . The biochemical link between PKC and NF-B activation has been delineated in recent studies (14, 16) . Mice lacking PKC show defective B cell proliferation upon BCR crosslinking and impaired humoral responses. In medium with no exogenous stimuli, PKC -deficient B cells die more rapidly than B cells from control wild-type mice. The poor survival of PKC -deficient B cells is associated with an inability to activate NF-B signaling and its downstream targets Bcl-x L and Bcl-2.
PKC is also involved in BAFF signaling pathways, which are critical for the survival of mature B cells. Moreover, the BAFF level controls the survival of autoreactive transitional and naive B cells (17, 18) . PKC is required for BAFF-controlled B cell metabolic fitness through phosphorylation of Akt (19) . Therefore, the involvement of PKC in both the BCR and BAFF signaling pathways provides a molecular mechanism for the poor survival and impaired peripheral maturation of PKC -deficient B cells in vitro and in vivo.
Taken together, the available information suggests that PKC inhibition could regulate the survival of autoreactive B cells and control the development of lupus. However, the role of PKC in the survival of lupus B cells and the development of this disease has not been specifically investigated. To address this issue, we used the Sle congenic mouse model that has been extensively used in lupus studies (20, 21) . We demonstrate here that a deficiency in PKC abolishes all lupus-associated phenotypes, such as high levels of autoantibodies in serum and lupus nephritis, as indicated by reductions in proteinuria and in antibody deposition in the kidneys. Our results also indicate that PKC deficiency renders lupus B cells anergic and impedes BCR-mediated NF-B activation. Importantly, PKC deficiency abolishes the spontaneous germinal center (GC) formation and generation of autoreactive plasma cells that characterize SLE and have critical roles in the pathogenesis of this autoimmune disease. Furthermore, we demonstrate that in vivo treatment with the PKCspecific inhibitor enzastaurin in mice with lupus ameliorates disease development, thus identifying PKC as a promising therapeutic target for the treatment of SLE.
MATERIALS AND METHODS

Generation of PKCβ-deficient Sle mice
The congenic mouse strains B6.Sle1 and B6.Sle1.Sle3 (22) and B6.PKC −/− mice (13, 23) were previously described. B6.Sle1 mice were bred with B6.PKC −/− mice to derive F1 mice. The F1 mice were mated to produce progenies, and the homozygotes at both the Sle and PKC −/− loci were identified by polymerase chain reaction (PCR) using primers specific for Sle1 (24) and PKC (23) . The generated PKC -deficient Sle mice were referred to as Sle1.PKC −/− mice and were used in our experiments. Similarly, B6.Sle1.Sle3 mice were bred with B6.PKC −/− mice, the homozygotes for Sle1, Sle3, and PKC −/− were selected using PCR primers (24) , and the resulting PKC -deficient Sle1.Sle3 mice were referred to as Sle1.Sle3.PKC −/− mice. For simplicity, B6 is henceforth omitted from the strain names, because all of the mice described had a B6 background. All animal procedures were approved by the Committee on Animal Resources at the University of Rochester.
Flow cytometric analysis
Single-cell suspensions were prepared from different tissues, and subsets of B cells and other types of cells were identified using a combination of antibodies, as previously described (25) . All antibodies were purchased from eBioscience, except allophycocyaninconjugated CD4 (BD Biosciences). Flow cytometry data were collected using FACSCalibur, FACSCanto II, or LSR II instruments (BD Biosciences) at the University of Rochester Flow Cytometry Core Facility and were analyzed using FlowJo software version 8.5.3 (Tree Star).
B cell purification, in vitro proliferation, and survival assays
For in vitro survival experiments, B cells purified using CD43 microbeads (Miltenyi Biotec) were either left untreated (control) or stimulated with 10 g/ml of anti-IgM F(ab ) 2 (Jackson ImmunoResearch) or lipopolysaccharide (LPS; 5 g/ml) for 22 hours. The cells were then stained and used for multicolor flow cytometric analysis.
To test the effect of the PKC inhibitor enzastaurin on the survival of human 9G4-positive B cells, peripheral blood was obtained from healthy donors according to protocols approved by the University of Rochester Medical Center Institutional Review Board. Peripheral blood mononuclear cells were isolated by a standard density-gradient centrifugation procedure. Naive B cells were purified using a Naive B Cell Isolation Kit (Miltenyi Biotec) according to the manufacturer's protocol. The purified naive B cells were treated with either DMSO (control) or enzastaurin (0.7 M; Selleck Chemicals) for 24 hours. The cells were stained with a 9G4 monoclonal antibody, using a Live/Dead Fixable Aqua Dead Cell Stain Kit (Invitrogen) to identify apoptotic cells in 9G4-positive cell populations.
Intracellular calcium measurements
The flux of Ca 2+ was measured as previously described (26) . Briefly, splenocytes (3 × 10 6 / ml) were loaded with 1 M Fura Red (Invitrogen) and then stained with phycoerythrinconjugated anti-B220 antibodies in loading buffer. Changes in intracellular Ca 2+ levels in B cells were analyzed using a BD FACSVantage SE system by measuring Fura Red fluorescence ratios in B220+ gated cells. A decrease in the fluorescence ratio indicates an increase in the intracellular Ca 2+ concentration. Data were displayed as the relative ratio of intensities of Fura Red for each cell over time and were analyzed using FlowJo software (Tree Star).
Enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunospot (ELISpot) assay for autoantibodies
Serum immunoglobulins of various isotypes were analyzed by ELISA (27) . Briefly, diluted sera were loaded onto precoated 96-well plates. Bound IgM or each IgG subtype was detected using alkaline phosphatase-conjugated goat anti-mouse IgM or IgG (SouthernBiotech) and an alkaline phosphatase substrate kit (Bio-Rad). Optical density at 405 nm was read on a BioTek Instruments microplate reader. IgG anti-double-stranded DNA (anti-dsDNA) antibody-secreting cells (ASCs) were detected by ELISpot assays, as previously described (28) .
Immunohistochemical analysis
Immunofluorescence analysis of frozen spleen sections was performed as previously described (29) . IgG deposition was detected with fluorescein isothiocyanate-conjugated goat anti-mouse IgG, IgG2b, or IgG2c (Molecular Probes). Images were obtained using a Leica DMRXA microscope (Carl Zeiss Instruments) and analyzed using SlideBook software. Consecutive slides were stained with hematoxylin and eosin and periodic acidSchiff at the University of Rochester Pathology Core Laboratory.
In vivo treatment
Two-month-old female Sle1.Sle3 mice were administered enzastaurin (1.5 mg in 200 l 10% acacia in water/per mouse; Selleck Chemicals) 4 times weekly for a period of 8 weeks, by oral gavage. Analysis of the mice was performed as described above.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.0. Two-group comparisons were analyzed using a Student's 2-tailed t-test. Data are presented as the mean ± SD. P values less than or equal to 0.05 were considered significant.
RESULTS
Effect of PKCβ deficiency on lupus development in Sle mice
To investigate the role of PKC in lupus B cell survival and in lupus development, we took advantage of the availability of the congenic Sle mouse model of lupus (22) and PKCdeficient mice (13) and generated PKC -deficient Sle mice by separately crossing PKC −/− mice with 2 congenic lupus mouse strains, Sle1 and Sle1.Sle3. We designated the offspring mice as Sle1.PKC −/− (homozygous for both the Sle locus and the PKC locus) and Sle1.Sle3.PKC −/− (homozygous for Sle1, Sle3, and PKC ). These 2 congenic strains were chosen because both Sle1 and Sle3 loci have an impact on B cells, and they represent 2 distinct stages of lupus severity (22, 30) . Compared with control mice, both Sle1 and Sle1.Sle3 mice displayed several features of systemic autoimmunity such as splenomegaly, increased activation of B cells and T cells, higher CD4:CD8 T cell ratios, and high antinuclear autoantibody (ANA) production. However, only Sle1.Sle3 bicongenic mice can develop full-blown lupus nephritis (29) .
One of the hallmarks of SLE in both humans and mice is the loss of tolerance to nuclear antigens, resulting in the production of ANAs such as antichromatin and anti-dsDNA (21) . Moreover, high levels of serum anti-dsDNA autoantibodies, especially IgG2a and IgG2c, are associated with the severity of glomerulonephritis (GN) in mice with lupus (29) . We thus examined the effect of PKC deletion on ANA production in Sle mice. As shown in Figure  1A , PKC deficiency resulted in a marked reduction in the levels of IgG1, IgG2b, and IgG2c anti-dsDNA and antihistone/anti-dsDNA autoantibodies in Sle mice. Notably, the levels of all tested autoantibody isotypes except IgG3, for which few differences were observed (results not shown), were significantly lower in Sle1.Sle3 PKC −/− mice than in Sle1.Sle3 mice with the wild-type PKC gene ( Figure 1A ), while total IgG levels were comparable in all 6 mouse strains used in this study (results not shown).
We also observed that PKC -deficient Sle mice displayed reduced levels of IgM antidsDNA (3.1-fold decrease in Sle1.PKC −/− mice versus Sle1 lupus mice [P = 0.01] and 9.5-fold decrease in Sle1.Sle3.PKC −/− mice versus Sle1.Sle3.PKC −/− mice [P = 0.01]) and IgM antihistone/anti-dsDNA (2.5-fold decrease in Sle1. PKC −/− mice and 6-fold decrease in Sle1.Sle3.PKC +/+ mice versus wild-type mice [P ≤ 0.01]), which is consistent with the notion that IgM autoantibodies play a role in the development of lupus nephritis (31) . As expected, we observed that total IgM levels in PKC -deficient Sle mice were much lower than those in Sle mice with wild-type PKC , in accordance with the observation that PKC −/− mice have a low level of serum IgM due to a significant decrease in the peritoneal B-1 cell population (13).
More significantly, besides the dramatic decrease in the number of serum autoantibodies in PKC -deficient Sle mice, the ability of PKC deficiency to alleviate SLE was further supported by both the absence of the immune complexes ( Figure 1B ) and the amelioration of histologic features of active GN, such as the glomerular enlargement and marked global mesangial and endocapillary proliferation that were present in Sle1.Sle3 mice ( Figure 1C) . Additionally, consistent with previous reports, ~70% of the 8-10-month-old Sle1.Sle3 mice developed high proteinuria levels (≥100 mg/dl) ( Figure 1D ) (29) . In contrast, the urinary protein concentration in age-matched PKC -deficient Sle mice was normal (<30 mg/dl; n =15 mice of each genotype). Collectively, our results demonstrated that the absence of PKC significantly attenuates the serologic, clinical, and histologic phenotypes characteristic of the Sle1 and Sle3 loci.
Characteristics of PKCβ-deficient Sle mice
Splenomegaly is a feature of murine lupus and is always associated with disease progression and severity (29) . Sle1 mice usually showed a moderate increase in spleen size compared with the control B6 mice, while Sle1.Sle3 bicongenic mice displayed marked splenomegaly Another characteristic of Sle1 and Sle1.Sle3 mice is expansion of the number of activated CD4+T cells and activated B cells (as judged by CD69 expression) and elevated CD4:CD8 T cell ratios (29, 32) . We observed that the loss of PKC prevented expansion of the populations of activated CD4+T cells and B220+cells and restored the CD4:CD8 T cell ratio in Sle mice (Figures 2B-D) .
One of the most striking phenotypes of PKC −/− mice is a severe reduction in the frequency of peritoneal B-1 cells (13) . Because expansion of the B-1 cell population has been associated with autoimmunity in both humans and mouse models (33,34), we analyzed peritoneal B cell populations (Figure 3 ). Sle1 and Sle1.Sle3 mice had a remarkable increase in the frequency of B-1a cells in their peritoneal cavities compared with B6 control mice ( Figures 3A and B) . This expansion was dramatically reduced in PKC -deficient Sle mice.
A detailed flow cytometric analysis of spleen and bone marrow B cells from PKC -deficient Sle mice did not reveal other obvious defects in B cell development, with one notable exception. PKC deficiency resulted in a several-fold decrease in the proportion of CD138+ plasma cells in spleen as well as bone marrow ( Figure 4A , and results not shown). This decrease in the frequency of ASCs was also reflected by the results of functional ELISpot assays ( Figure 4B) , consistent with the earlier ELISA results showing greatly decreased serum levels of IgG anti-dsDNA antibodies in PKC -deficient Sle mice ( Figure 1A ).
PKC deficiency resulted in the reversal of another SLE-associated feature of great interest and relevance to the overall disease process. PKC -deficient Sle mice lacked the spontaneous GC formation that is characteristic of mice with lupus ( Figure 4C ). The diminished number of GC B cells (B220+GL7+CD95+) in PKC -deficient Sle mice ( Figure  4D ) may contribute to the decreased de novo production of plasma cells in GC reactions.
Anergic B cell phenotype in PKCβ-deficient Sle mice
We also assessed the functional status of PKC -deficient Sle mice. Because PKC -deficient B cells are characterized by drastically decreased proliferative responses to IgM-mediated BCR crosslinking (14, 15) , we sought to determine whether PKC deletion also leads to impaired BCR signaling in B cells from Sle mice. As shown in Figure 5A , deletion of PKC diminished the proliferation response of B cells from Sle mice to anti-IgM stimulation but not to LPS stimulation, which is mediated by a different receptor (Toll-like receptor 4). Consistently, up-regulation of activation markers such as CD69 and CD86 was attenuated in PKC -deficient Sle mice ( Figure 5A ).
In accordance with the previous observation that PKC -deficient B cells exhibited poor survival in vitro in the absence of a stimulus (14, 15, 35) , B cells from PKC -deficient Sle mice had a shorter lifespan than those from Sle mice ( Figure 5B ). In contrast, B cells from B6.Sle1.Sle3 mice showed prolonged survival and a stronger response to anti-IgM stimulation ( Figures 5A and B) . The B cells from B6.Sle1 mice had a slightly higher rate of survival compared with B cells from the B6 control littermates. This attenuated BCR response and the shortened lifespan in PKC -deficient Sle mice are reminiscent of antihuman erythroleukemia cell line and anti-dsDNA-transgenic B cells, which were rendered anergic following long-term stimulation with the corresponding self antigens.
Previous studies indicated that the poor survival of PKC -deficient B cells correlates well with their inability to up-regulate BCR-mediated NF-B signaling (14, 15) . We therefore hypothesized that a deficiency in PKC uncouples BCR-mediated NF-B signaling in the B cells of Sle mice. To test this possibility, we cultured splenocytes from different mouse strains in medium, in the presence or absence of anti-IgM F(ab ) 2 stimulation, for 24 hours. B cells from PKC -deficient Sle mice failed to induce the expression of the antiapoptotic protein Bcl-x L , an NF-B target ( Figure 5C ), or phosphorylation of I B in response to anti-IgM stimulation (results not shown). These observations suggest that the inability of PKC -deficient cells to up-regulate BCR-mediated NF-B activation is responsible for the shortened lifespan of B cells from PKC -deficient Sle mice.
Abnormal calcium signaling has been associated with anergic B cells. We thus investigated the effect of PKC deletion on calcium signaling in B cells from Sle mice. Both PKC −/− mice and PKC -deficient Sle mice showed a marked decrease in Ca 2+ flux upon BCR stimulation ( Figure 5D ), further supporting the notion that PKC deficiency renders lupus B cells anergic.
Sensitivity of lupus B cells to PKCβ inhibition
It was reported previously that, upon selective PKC blockade, mature B cells respond to BCR engagement in a manner similar to that of immature B cells and undergo apoptosis, indicating that PKC is a critical factor determining the fate of B cells in terms of apoptosis or survival (36) . This observation, combined with our studies described above, raises the possibility of inhibiting mature autoreactive B cell survival through PKC inhibition. We thus examined whether lupus B cells could be induced to undergo apoptosis by selective inhibition of PKC with a pharmacologic agent (37) . As shown in Figure 6A , enzastaurin, a well-tolerated PKC -specific inhibitor, induced apoptosis of lupus B cells in the presence of BCR signaling, suggesting that lupus B cells depend on PKC signaling for survival.
We next sought to determine whether the PKC inhibitor enzastaurin exhibits a similar effect on human autoreactive B cells. We analyzed the effect of this intervention on cells expressing the 9G4 idiotype; 9G4-determined autoreactivity is censored in healthy subjects but is expanded in patients with SLE (38) . Indeed, due to their autoreactivity, human 9G4-positive B cells were more sensitive to PKC inhibition than were 9G4-negative B cells ( Figure 6B ), indicating that human autoreactive B cells are highly dependent on PKC for survival.
Having shown that enzastaurin inhibited the survival of both Sle mouse B cells and human autoreactive B cells, we investigated the effect of enzastaurin on disease development in mice with lupus. We treated 2-month-old Sle1.Sle3 mice, when they were disease free (22) , with enzastaurin over an 8-week period. Compared with vehicle-treated control mice, Sle1.Sle3 mice treated with enzastaurin showed a 43% decrease in spleen size (the average spleen weights of Sle1.Sle3 mice with and without treatment were 159 mg and 279 mg, respectively; n = 7), and there was a significant reduction in the frequency of activated CD4+T cells (an average of 25.3 × 10 6 CD69+CD4+ T cells/spleen in control mice compared with an average of 15.2 × 10 6 CD69+CD4+ T cells/spleen in enzastaurin-treated mice). In addition, the mice treated with enzastaurin displayed remarkable decreases in the serum levels of anti-dsDNA and antihistone/anti-dsDNA autoantibodies ( Figure 6C ). More significantly, the severity of renal disease in enzastaurin-treated mice was diminished, as reflected by decreased GN ( Figure 6D ) and proteinuria (100% of the treated Sle1.Sle3 mice remained free of proteinuria [<30 mg/dl; n = 7]). In contrast, 5 of 7 untreated mice had urea protein levels of ≥100 mg/dl. Taken together, these results showed that enzastaurin treatment prevented lupus development in mice, suggesting the possibility of targeting PKC as a therapeutic strategy for lupus.
DISCUSSION
In the present study, we demonstrate that PKC is required for disease development in the Sle mouse model of lupus. Remarkably, PKC deficiency reversed all tested lupus phenotypes including spontaneous formation of GCs, production of autoantibodies, splenic cellular abnormalities, activation of B cells and T cells, and expansion of CD4:CD8 T cell ratios. Of critical importance, PKC deficiency dramatically alleviated clinical and histologic manifestations of GN, one of the main organ targets of SLE and the major determinant of disease outcome in human SLE. Also of note, PKC deficiency induced a preferential reduction in the number of SLE-related anti-dsDNA and antihistone antibodies and anti-dsDNA ASCs relative to total IgG.
Taken together, the observations that GC formation is inhibited in PKC -deficient Sle mice and that pharmacologic inhibition of PKC preferentially increased apoptotic death in murine lupus and human autoreactive B cells suggest that PKC blockade preferentially targets activated B cells that actively participate in ongoing autoimmune reactions and therefore represents a promising avenue for the therapeutic targeting of B cells in SLE.
Given that PKC regulates both the BCR and BAFF signaling pathways, which are able to potentiate each other and are implicated genetically and functionally in the pathogenesis of SLE (1, 2, 18) , the beneficial effects of PKC inhibition would include the enforcement of tolerance in developing immature autoreactive B cells, induction of anergy in mature B cells, and suppression of GC formation and development of auto-reactive plasma cells. All of these actions are supported by our data, with the exception of the functionality of early tolerance checkpoints, which were not formally analyzed in this work.
How does PKC exert such a great impact on lupus development? One possible explanation is that the absence of PKC function may induce B cell anergy, which is a major mechanism of B cell tolerance (39) . Similar to the role of PKC in T cells, PKC has been reported to play a critical role in determining whether B cells are tolerant or activated (36) . Consistent with this function, B cells from PKC -deficient Sle mice display typical anergic features previously identified in auto-reactive immunoglobulin-transgenic mice, such as a shortened lifespan, lack of proliferative responsiveness to BCR stimulation, failure to up-regulate activation markers, and impaired calcium mobilization after BCR engagement.
Effective antigen stimulation of B cells requires activation of the NF-B pathway, which is critical for B cell survival, and PKC is required for BCR-mediated NF-B signaling in B cells. Consistent with the notion that the NF-B pathway is not induced in tolerant cells, we observed that PKC deficiency results in the uncoupling of BCR-induced NF-B activation in lupus B cells. We observed that Bcl-x L , a downstream target of NF-B, was not upregulated in PKC -deficient B cells from Sle mice. The inability to up-regulate antiapoptotic genes upon BCR stimulation is likely to be responsible, at least in part, for the shortened lifespan of PKC -deficient B cells and may contribute to the reversal of lupus features observed in PKC -deficient Sle mice.
PKC deficiency may also contribute to amelioration of T cell-mediated autoimmunity by compromising the antigen presentation and costimulatory functions of B cells (1, 40, 41) . Indeed, we observed that PKC -deficient B cells were not able to efficiently up-regulate the critical T cell-costimulatory molecules CD80 and CD86 in response to BCR stimulation (data not shown). Consistent with these results, PKC -deficient mice displayed an impaired response to T cell-dependent antigens (trinitrophenyl [TNP]-ovalbumin), because the serum level of IgG anti-TNP in PKC -deficient Sle mice was only ~30% of the IgG level in lupus mice 4 weeks after immunization (data not shown). The relevance of these findings for lupus is also highlighted by the observations that human lupus B cells display marked upregulation of CD86 expression, and that anti-CD80 antibody treatment induces a dramatic decrease in anti-dsDNA production and reduced kidney pathology in mice with lupus (42).
One striking phenotype of PKC -deficient Sle mice is a dramatic decrease in the production of peritoneal B-1 cells (Figure 3) , similar to what was previously observed for PKCknockout mice. Although the role of B-1 cells in lupus is controversial, multiple studies indicate that B-1a cells may be involved in the development of lupus through the production of autoantibodies (33) . Additionally, accumulations of large numbers of B-1 cells in peritoneal and, to a lesser extent, spleen cells have been shown to be associated with mouse models of lupus, including Sle mice (34, 43) . Deletion of B-1 cells by hypotonic shock reduced disease severity in (NZB × NZW)F1 mice with lupus (44) . B-1 cells could also contribute to lupus manifestations in the following ways: autoantibody production, interleukin-10-mediated B cell proliferation (45) , and enhanced antigen-presenting capabilities (46) .
In addition to participating in BCR-mediated NF-B activation, PKC has a crucial role in BAFF-mediated Akt activation, by phosphorylating Akt at Ser 473 (19) . Because it is well documented that the bioenergenic state of T cells correlates directly with their survival (47) , and because BAFF controls B cell survival by regulating B cell metabolic fitness (19) , we speculate that PKC deficiency would impair the fitness of lupus B cells, resulting in poor survival of these cells. Moreover, BAFF is critical for the survival of autoreactive B cells, and excess BAFF induces clinical autoimmunity (48) . Therefore, future studies will be aimed at understanding both the effects of BAFF stimulation in PKC -deficient B cells and the potential clinical benefit of PKC deficiency in BAFF-mediated autoimmunity. Our initial studies have already indicated that, consistent with a previous report (19) In summary, our results illustrate that PKC plays a critical role in disease development in a mouse model of SLE, and that PKC deficiency induces striking clinical, serologic, and histologic improvement. Furthermore, we demonstrate that inhibition of PKC with the pharmacologic inhibitor enzastaurin can preferentially impair the survival of human autoreactive B cells (9G4 positive). Although our experiments were performed only in an Sle mouse model, and exploration with other mouse models of lupus remains to be carried out, the collective evidence presented in this report strongly supports the notion that targeting PKC may represent a promising treatment of human SLE. PKC inhibitors for treatment of SLE may be used either as single agents or in combination with the recently approved anti-BAFF inhibitors (49, 50) or other small-molecule drugs such as a Syk inhibitor. 
